RemeGen Co EBITDA per osake

Mitä RemeGen Co tekee? RemeGen Co Ltd, listed on the Shanghai Stock Exchange under ticker 688331.SS, is a biotechnology company headquartered in Yantai, China. The company went public on November 9, 2020, and currently employs 3,332 full-time staff. RemeGen focuses on the research, development, and manufacturing of innovative biopharmaceuticals, with a particular emphasis on therapeutic antibody drugs. Its product portfolio includes antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. The company's main products are tetacept (RC18), veldicitumab (RC48), and dual-target fusion protein (RC28), which are designed to treat conditions such as autoimmune diseases, oncology, and ophthalmology. RemeGen primarily operates within the domestic Chinese market, targeting major disease areas with its biopharmaceutical solutions. The company's website is www.remegen.cn, providing further information on its operations and products. RemeGen's business model centers on the discovery, development, and commercialization of advanced therapeutic antibodies, aiming to address significant unmet medical needs in the healthcare sector. With a strong focus on innovation, the company is positioned to contribute to the growing biotechnology landscape in China. Its operations reflect a commitment to developing cutting-edge treatments for complex health conditions, leveraging its expertise in antibody-based therapies. RemeGen Co on yksi Eurpooliin suosituimmista yhtiöistä.